Maria Claudia Cruz Andreoli
Federal University of São Paulo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maria Claudia Cruz Andreoli.
Hemodialysis International | 2009
Aline Trevisan Peres; Maria Aparecida Dalboni; Maria Eugênia Fernandes Canziani; Silvia Regina Manfredi; José Tarcísio Giffoni de Carvalho; Marcelo Costa Batista; Lilian Cuppari; Aluísio Barbosa Carvalho; Rosa Maria Affonso Moysés; Nádia K Guimarães; Vanda Jorgetti; Maria Claudia Cruz Andreoli; Sergio Antonio Draibe; Miguel Cendoroglo
It has been suggested that phosphate binders may reduce the inflammatory state of hemodialysis (HD) patients. However, it is not clear whether it has any effect on oxidative stress. The objective of this study was to evaluate the effect of sevelamer hydrochloride (SH) and calcium acetate (CA) on oxidative stress and inflammation markers in HD patients. Hemodialysis patients were randomly assigned to therapy with SH (n=17) or CA (n=14) for 1 year. Before the initiation of therapy (baseline) and at 12 months, we measured in vitro reactive oxygen species (ROS) production by stimulated and unstimulated polymorphonuclear neutrophils and serum levels of tumor necrosis factor α, interleukin‐10, C‐reactive protein, and albumin. There was a significant reduction of spontaneous ROS production in both groups after 12 months of therapy. There was a significant decrease of Staphylococcus aureus stimulated ROS production in the SH group. There was a significant increase in albumin serum levels only in the SH group. In the SH group, there was also a decrease in the serum levels of tumor necrosis factor α and C‐reactive protein. Our results suggest that compared with CA treatment, SH may lead to a reduction in oxidative stress and inflammation. Therefore, it is possible that phosphate binders exert pleiotropic effects on oxidative stress and inflammation, which could contribute toward decreasing endothelial injury in patients in HD.
Nephrology Dialysis Transplantation | 2015
Thyago Proença de Moraes; Maria Claudia Cruz Andreoli; Maria Eugênia Fernandes Canziani; Dirceu Reis da Silva; Jacqueline Socorro Costa Teixeira Caramori; Daniela Ponce; Hélio Vida Cassi; Kleyton de Andrade Bastos; Danyelle Romana Alves Rio; Sérgio Wyton Lima Pinto; Sebastião Rodrigues Ferreira Filho; Ludimila G. Campos; Marcia Olandoski; José Carolino Divino-Filho; Roberto Pecoits-Filho
BACKGROUND Insulin resistance is a common risk factor in chronic kidney disease patients contributing to the high cardiovascular burden, even in the absence of diabetes. Glucose-based peritoneal dialysis (PD) solutions are thought to intensify insulin resistance due to the continuous glucose absorption from the peritoneal cavity. The aim of our study was to analyse the effect of the substitution of glucose for icodextrin on insulin resistance in non-diabetic PD patients in a multicentric randomized clinical trial. METHODS This was a multicenter, open-label study with balanced randomization (1:1) and two parallel-groups. Inclusion criteria were non-diabetic adult patients on automated peritoneal dialysis (APD) for at least 3 months on therapy prior to randomization. Patients assigned to the intervention group were treated with 2L of icodextrin 7.5%, and the control group with glucose 2.5% during the long dwell and, at night in the cycler, with a prescription of standard glucose-based PD solution only in both groups. The primary end-point was the change in insulin resistance measured by homeostatic model assessment (HOMA) index at 90 days. RESULTS Sixty patients were included in the intervention (n = 33) or the control (n = 27) groups. There was no difference between groups at baseline. After adjustment for pre-intervention HOMA index levels, the group treated with icodextrin had the lower post-intervention levels at 90 days in both intention to treat [1.49 (95% CI: 1.23-1.74) versus 1.89 (95% CI: 1.62-2.17)], (F = 4.643, P = 0.03, partial η(2) = 0.078); and the treated analysis [1.47 (95% CI: 1.01-1.84) versus 2.18 (95% CI: 1.81-2.55)], (F = 7.488, P = 0.01, partial η(2) = 0.195). CONCLUSIONS The substitution of glucose for icodextrin for the long dwell improved insulin resistance measured by HOMA index in non-diabetic APD patients.
Renal Failure | 2004
Camila Sardenberg; Paulo Suassuna; Renato Watanabe; Maria Claudia Cruz Andreoli; Maria Aparecida Dalboni; Victor F. Seabra; Sergio Antonio Draibe; Miguel Cendoroglo Neto; Bertrand L. Jaber
Hemodialysis (HD) and peritoneal dialysis are associated with inflammatory events and immunological incompetence. The purpose of this study was to evaluate the effect of both uremia and dialysis modality on the production of cytokines and reactive oxygen species (ROS) by monocytes. four groups of subjects were studied: 28 chronic kidney disease (CKD) patients, 14 chronic HD patients, 14 patients on continuous ambulatory peritoneal dialysis (CAPD) patients, and 14 healthy volunteers. peripheral blood mononuclear cells (PBMC) were isolated from blood samples and incubated for 24 hr with or without lipopolysaccharide (LPS). TNF‐α and IL‐10 production by PBMC and serum levels of these cytokines were quantified by ELISA. Aliquots of whole blood were incubated in vitro and ROS production and phagocytosis were quantified by flow cytometry. Compared to the control group, Staphylococcus aureus–stimulated ROS production by monocytes was significantly lower in the HD group. The highest levels of unstimulated TNF‐α production in vitro were observed in the HD group. In the CKD group, as well as in the whole population, there were a negative correlation between TNF‐α production by unstimulated PBMC and ROS production by S. aureus–stimulated monocytes and a positive correlation between PMA‐stimulated ROS production by monocytes and unstimulated and LPS‐stimulated IL‐10 production by PBMC suggesting that the pro‐inflammatory state in CKD patients is associated with decreased response to infectious challenges.
Therapeutic Apheresis and Dialysis | 2010
Érika Bevilaqua Rangel; Breno Pannia Espósito; Fabiana D Carneiro; Ana Cláudia Mallet; Ana Cristina Carvalho de Matos; Maria Claudia Cruz Andreoli; Nadia Guimaraes-Souza; Bento Fc Santos
Iron supplementation in hemodialysis patients is fundamental to erythropoiesis, but may cause harmful effects. We measured oxidative stress using labile plasma iron (LPI) after parenteral iron replacement in chronic hemodialysis patients. Intravenous iron saccharate (100 mg) was administered in patients undergoing chronic hemodialysis (N = 20). LPI was measured by an oxidant‐sensitive fluorescent probe at the beginning of dialysis session (T0), at 10 min (T1), 20 min (T2), and 30 min (T3) after the infusion of iron and at the subsequent session; P < 0.05 was significant. The LPI values were significantly raised according to the time of administration and were transitory: −0.02 ± 0.20 µmol/L at the beginning of the first session, 0.01 ± 0.26 µmol/L at T0, 0.03 ± 0.23 µmol/L at T1, 0.09 ± 0.28 µmol/L at T2, 0.18 ± 0.52 µmol/L at T3, and −0.02 ± 0.16 µmol/L (P = 0.001 to 0.041) at the beginning of the second session. The LPI level in patients without iron supplementation was −0.06 ± 0.16 µmol/L. Correlations of LPI according to time were T1, T2, and T3 vs. serum iron (P = 0.01, P = 0.007, and P = 0.0025, respectively), and T2 and T3 vs. transferrin saturation (P = 0.001 and P = 0.0003, respectively). LPI generation after intravenous saccharate administration is time‐dependent and transitorily detected during hemodialysis. The LPI increment had a positive correlation to iron and transferrin saturation.
PLOS ONE | 2017
Maria Claudia Cruz Andreoli; Nádia Karina Guimarães De Souza; Adriano Luiz Ammirati; Thais Nemoto Matsui; Fabiana D Carneiro; Ana Claudia Mallet De Souza Ramos; Ilson Jorge Iizuca; Maria Paula Vilela Coelho; Rogério Carballo Afonso; Ben Hur Ferraz-Neto; M.D. Almeida; Marcelino de Souza Durão; Marcelo Costa Batista; Julio Cesar Martins Monte; Virgilio Gonçalves Pereira; Oscar Pavão dos Santos; Bento Santos
Renal dysfunction frequently occurs during the periods preceding and following orthotopic liver transplantation (OLT), and in many cases, renal replacement therapy (RRT) is required. Information regarding the duration of RRT and the rate of kidney function recovery after OLT is crucial for transplant program management. We evaluated a sample of 155 stable patients undergoing post-intensive care hemodialysis (HD) from a patient population of 908 adults who underwent OLT. We investigated the average time to renal function recovery (duration of RRT required) and determined the risk factors for remaining on dialysis > 90 days after OLT. Log-rank tests were used for univariate analysis, and Cox proportional hazards models were used to identify factors associated with the risk of remaining on HD. The results of our analysis showed that of the 155 patients, 28% had pre-OLT diabetes mellitus, 21% had pre-OLT hypertension, and 40% had viral hepatitis. Among the patients, the median MELD (Model for End-Stage Liver Disease) score was 27 (interquartile range [IQR] 22-35). When they were listed for liver transplantation, 32% of the patients had serum creatinine (Scr) levels > 1.5 mg/dL or were on HD, and 50% had serum creatinine (Scr) levels > 1.5 mg/dL or were on HD at the time of OLT. Of the transplanted patients, 25% underwent pre-OLT intermittent HD, and 14% and 41% underwent continuous renal replacement therapy (CRRT) pre-OLT and post-OLT, respectively. At 90 days post-OLT, 118 (76%) patients had been taken off dialysis, and 16 (10%) patients had died while undergoing HD. The median recovery time of these post-OLT patients was 33 (IQR 27–39) days. In the multivariate analysis, fulminant hepatic failure as the cause of liver disease (p<0.001), the absence of pre-OLT hypertension (p = 0.016), a lower intraoperative fresh-frozen plasma (FFP) transfusion volume (p = 0.019) and not undergoing pre-OLT intermittent HD (p = 0.032) were associated with performing RRT for less than 90 days. Therefore, a high proportion of OLT patients showed improved renal function after OLT, and those who were diagnosed with fulminant hepatic failure, had no pre-OLT hypertension, received a lower transfused volume of intraoperative FFP and did not undergo pre-OLT intermittent HD had a higher probability of recovery.
Einstein (São Paulo) | 2011
Oliveira; Maria Aparecida Dalboni; Ilson Jorge Iizuka; Manfredi; Nádia K Guimarães; Maria Claudia Cruz Andreoli; Ana Cristina Carvalho de Matos; Marcelo Costa Batista; Santos Bf; Cendoroglo Neto M
OBJECTIVE Reuse of hemodialysis filters is a standard practice and the sterilizing chemical most often employed is peracetic acid. Before starting the dialysis session, filters and lines are checked for residual levels of peracetic acid by means of a non-quantitative colorimetric test that is visually interpreted. The objective of this study was to investigate a new quantitative spectrophotometric test for detection of peracetic acid residues. METHODS Peracetic acid solutions were prepared in concentrations ranging from 0.01 to 10 ppm. A reagent (potassium-titanium oxide + sulfuric acid) was added to each sample in proportions varying from 0.08 to 2.00 drops/mL of solution. Optical densities were determined in a spectrophotometer using a 405-nm filter and subjected to visual qualitative test by different observers. RESULTS A relation between peroxide concentrations and respective optical densities was observed and it was linear with R2 > 0.90 for all reagent/substrate proportions. The peak optical densities were obtained with the reagent/substrate ratio of 0.33 drops/mL, which was later standardized for all further experiments. Both qualitative and quantitative tests yielded a specificity of 100%. The quantitative test was more sensitive than the qualitative test and resulted in higher positive and negative predictive values. There was a difference between observers in the qualitative test and some samples with significant amounts of peroxide were not detected. CONCLUSION A quantitative spectrophotometric test may improve detection of residues of peracetic acid when compared to the standard visual qualitative test. This innovation may contribute to the development of safer standards for reuse of hemodialysis filters.
Critical Care | 2001
Camila Sardenberg; Paulo Suassuna; Renato Watanabe; Maria Aparecida Dalboni; Maria Claudia Cruz Andreoli; F Calvo; Sergio Antonio Draibe; Bl Jaber; Miguel Cendoroglo
It has been suggested that PMN apoptosis is increased in dialysis patients and may contribute to cellular dysfunction. We investigated the effect of treatment modality and biochemical parameters on PMN apoptosis and function. Blood was drawn from 17 controls, 17 patients with chronic renal failure (CRF; creatinine clearance 28 ± 14 ml/min/1.73 m2), 10 hemodialysis (HD) and 11 CAPD patients. Upon collection, whole blood aliquots were incubated in RPMI-1640 with propidium iodide (PI)-labeled Saureus (SA), PMA, fMLP or LPS for 30 min. Cells were then stained with DCFH-DA and analyzed by flow cytometry, in order to quantify phagocytosis and H2O2 release by PMN. After separation by gradient centrifugation, PMN were stained with Annexin-V and PI in order to quantify apoptosis by flow cytometry. The results were correlated with blood levels of urea, creatinine, bicarbonate, albumin and PTH. Results are presented as means ± SD. Among CRF and HD patients, there was an inverse correlation between apoptosis and SA- (r = 0.62, P = 0.01 and r = 0.89, P = 0.02, respectively) and LPS-stimulated H2O2 release (r = 0.68, P = 0.005 and r = 0.61, P = 0.058, respectively). No biochemical parameters correlated with apoptosis or cellular functions. In summary, PMN apoptosis contributes to cellular malfunction in uremia, but does not account for all the dysfunction. Hence, it is possible that other uremic toxins affect cell performance independently of apoptosis. Table
Nephrology Dialysis Transplantation | 2006
Camila Sardenberg; Paulo Suassuna; Maria Claudia Cruz Andreoli; Renato Watanabe; Maria Aparecida Dalboni; Silvia Regina Manfredi; Oscar Pavão dos Santos; Esper G. Kallas; Sergio Antonio Draibe; Miguel Cendoroglo
Artificial Organs | 2004
Elsa Alidia Petry Gonçalves; Maria Claudia Cruz Andreoli; Renato Watanabe; Maria Cecília de Santos Freitas; Alessandra Coelho Pedrosa; Silvia Regina Manfredi; Sergio Antonio Draibe; Miguel Cendoroglo; Maria Eugênia Fernandes Canziani
Artificial Organs | 2003
Maria Aparecida Dalboni; Camila Sardenberg; Maria Claudia Cruz Andreoli; Renato Watanabe; Maria Eugênia Fernandes Canziani; Bento Fortunato Cardoso dos Santos; Orfeas Liangos; Bertrand L. Jaber; Sergio Antonio Draibe; Miguel Cendoroglo